To evaluate the safety and tolerability of pegargiminase (ADI-PEG) and ifosfamide in combination with standard-dose radiotherapy in soft tissue sarcoma (STS).
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given ...
Dose Escalation: To evaluate the safety and tolerability of peposertib in combination with low-dose liposomal doxorubicin as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level. Dose Escalation: To determine the recommended phase 2 dose (RP2D) of liposomal doxorubicin and peposertib combination and determine the maximal tolerated dose (MTD) if identified. Dose Ex...
Determine the efficacy of treatment with weekly doxorubicin chemotherapy in anthracycline-naïve elderly patients with advanced or metastatic LMS of soft tissue.
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a typ...
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
This study wants to find a new combination of drugs that is safe and effective to treat people who have bone cancer that has come back or not responded to other treatments.
The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and "personalized medicine".
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.